ArticleFrontiers in immunology2025

Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer.

Yufan Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.